Anti-Hypertensive Drugs - Egypt

Egypt

Highlights

The revenue of the Anti-Hypertensive Drugs market in Egypt is projected to reach US$24.29m in 2024.
It is expected to demonstrate an annual growth rate (CAGR 2024-2029) of 1.99%, leading to a market volume of US$26.81m by 2029.
In comparison to other countries, United States is expected to generate the highest revenue, amounting to US$12.29bn in 2024.
Egypt's growing middle class and increasing prevalence of hypertension are driving the demand for anti-hypertensive drugs in the country.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Anti-Hypertensive Drugs market in Egypt has been experiencing a steady growth in recent years.

Customer preferences: Egypt has a high prevalence of hypertension, with approximately one-third of the adult population suffering from the condition. As a result, there is a high demand for anti-hypertensive drugs in the country. Patients in Egypt prefer affordable drugs that are easily accessible and have minimal side effects. They also prefer drugs that are manufactured by reputable pharmaceutical companies.

Trends in the market: The Anti-Hypertensive Drugs market in Egypt is primarily driven by the increasing prevalence of hypertension in the country. The market has witnessed the introduction of new drugs that are more effective and have fewer side effects. There has also been an increase in the number of generic drugs in the market, which has led to increased competition and lower prices. The market has also witnessed an increase in online pharmacies, which has made it easier for patients to access drugs.

Local special circumstances: The Egyptian government has implemented various policies aimed at improving access to healthcare in the country. These policies have led to an increase in the number of healthcare facilities in the country, which has improved access to anti-hypertensive drugs. However, there are still challenges in the distribution of drugs, especially in rural areas.

Underlying macroeconomic factors: Egypt has experienced economic growth in recent years, which has led to an increase in disposable income. This has led to an increase in healthcare spending, including spending on anti-hypertensive drugs. The government has also implemented policies aimed at improving the pharmaceutical industry in the country, which has led to an increase in the production of drugs locally. However, the devaluation of the Egyptian pound has led to an increase in drug prices, which has made it difficult for some patients to access drugs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.